180 related articles for article (PubMed ID: 27875519)
1. Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours.
Childs A; Vesely C; Ensell L; Lowe H; Luong TV; Caplin ME; Toumpanakis C; Thirlwell C; Hartley JA; Meyer T
Br J Cancer; 2016 Dec; 115(12):1540-1547. PubMed ID: 27875519
[TBL] [Abstract][Full Text] [Related]
2. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.
Rufini V; Lorusso M; Inzani F; Pasciuto T; Triumbari EKA; Grillo LR; Locco F; Margaritora S; Pescarmona E; Rindi G
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4182-4193. PubMed ID: 35674739
[TBL] [Abstract][Full Text] [Related]
3. Comparison of gallium-68 somatostatin receptor and
Liu X; Li N; Jiang T; Xu H; Ran Q; Shu Z; Wu J; Li Y; Zhou S; Zhang B
Hell J Nucl Med; 2020; 23(2):188-200. PubMed ID: 32716410
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.
Kaemmerer D; Peter L; Lupp A; Schulz S; Sänger J; Prasad V; Kulkarni H; Haugvik SP; Hommann M; Baum RP
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1659-68. PubMed ID: 21626438
[TBL] [Abstract][Full Text] [Related]
5. Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies.
Srirajaskanthan R; Watkins J; Marelli L; Khan K; Caplin ME
Neuroendocrinology; 2009; 89(3):308-14. PubMed ID: 19307732
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
9. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
[TBL] [Abstract][Full Text] [Related]
10. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
[TBL] [Abstract][Full Text] [Related]
11. Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients.
Muscarella LA; D'Alessandro V; la Torre A; Copetti M; De Cata A; Parrella P; Sperandeo M; Pellegrini F; Frusciante V; Maiello E; Merla G; Fazio VM; Vendemiale G
Cell Oncol (Dordr); 2011 Oct; 34(5):435-41. PubMed ID: 21503779
[TBL] [Abstract][Full Text] [Related]
12. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.
Hicks RJ
Cancer Imaging; 2010 Oct; 10 Spec no A(1A):S83-91. PubMed ID: 20880795
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at
Ruuska T; Ramírez Escalante Y; Vaittinen S; Gardberg M; Kiviniemi A; Marjamäki P; Kemppainen J; Jyrkkiö S; Minn H
Acta Oncol; 2018 Feb; 57(2):283-289. PubMed ID: 28686510
[TBL] [Abstract][Full Text] [Related]
14. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine neoplasms and somatostatin receptor subtypes expression.
Hankus J; Tomaszewska R
Nucl Med Rev Cent East Eur; 2016; 19(2):111-7. PubMed ID: 27479788
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.
Graf J; Pape UF; Jann H; Denecke T; Arsenic R; Brenner W; Pavel M; Prasad V
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):881-894. PubMed ID: 31414209
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice.
Kiesewetter B; Mazal P; Kretschmer-Chott E; Mayerhoefer ME; Raderer M
ESMO Open; 2022 Jun; 7(3):100478. PubMed ID: 35525183
[TBL] [Abstract][Full Text] [Related]
18. Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging.
Refardt J; Zandee WT; Brabander T; Feelders RA; Franssen GJH; Hofland LJ; Christ E; de Herder WW; Hofland J
Endocr Relat Cancer; 2020 Nov; 27(11):615-624. PubMed ID: 33032265
[TBL] [Abstract][Full Text] [Related]
19. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.
John M; Meyerhof W; Richter D; Waser B; Schaer JC; Scherübl H; Boese-Landgraf J; Neuhaus P; Ziske C; Mölling K; Riecken EO; Reubi JC; Wiedenmann B
Gut; 1996 Jan; 38(1):33-9. PubMed ID: 8566856
[TBL] [Abstract][Full Text] [Related]
20. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
